Efavirenz: Uses, Interactions, Mechanism of Action - DrugBank …
Efavirenz (dideoxyinosine, ddI) is an oral non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a synthetic purine derivative and, similar to zidovudine, zalcitabine, and stavudine. Efavirenz was originally approved specifically for the treatment of HIV infections in patients who failed therapy with zidovudine.
Efavirenz - Wikipedia
Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. [1] It is generally recommended for use with other antiretrovirals. [ 1 ]
Efavirenz - StatPearls - NCBI Bookshelf
2024年2月28日 · As a member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, efavirenz is an integral component of antiretroviral therapy (ART) regimens. By selectively inhibiting the reverse transcriptase enzyme, an essential catalyst for transcribing viral RNA into DNA, efavirenz disrupts the replication process of the human ...
Efavirenz: History, Development and Future - PMC - National …
2022年12月31日 · Efavirenz is the first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat immunodeficiency virus (HIV) type 1 infection or prevent the spread of HIV. It is sold under the brand names Sustiva ® and Stocrin ® and is the lead compound of a series of benzoxazinones developed initially by DuPont Pharmaceuticals (Figure ...
依法韦仑 - 维基百科，自由的百科全书
依法韋侖（英語： Efavirenz ，簡稱EFV） 以Sustiva等品牌於市面販售，是一種用於治療和預防愛滋病的抗反轉錄病毒藥物。 [1] 通常是建議與其他抗反轉錄病毒藥物一起使用。 [1] 它也可用於針刺傷害或其他潛在暴露後的預防感染用途。
Efavirenz Teva | European Medicines Agency (EMA)
The active substance in Efavirenz Teva, efavirenz, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells in the body and make more viruses.
Efavirenz demonstrated additive to antagonistic antiviral activity in cell culture with atazanavir. Efavirenz was not antagonistic with adefovir, used for the treatment of hepatitis B virus...
CPIC® Guideline for Efavirenz based on CYP2B6 genotype
Apparent oral clearance (CL/F) of efavirenz (600 mg/day) in HIV-positive individuals genotyped for CYP2B6 variants. a Some of the tables included in the guideline may have been updated online, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page ...
Efavirenz 600mg film-coated tablets - Summary of Product
Efavirenz is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg.
Efavirenz: a review - PubMed
Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection.
- 某些结果已被删除